Andrew Filderman, MD
Pulmonary Disease · Rockport, MENPI 1093705766
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $192,155 of the $209,688 with a category attached, or 91.6%. GSK accounts for 76.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $46,127 and has fallen 77.9% since, to $10,192 in 2025. Among pulmonary disease clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $665.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$161K
- AstraZeneca$43K
- Boehringer Ingelheim$4K
- Viiv Healthcare Company$600
- Genentech USA, Inc.$282
- Sanofi$233
- plus $649 from 11 others
What the payments were for
- Consulting fees$2,2621%
- Speaking & faculty fees$192,15592%
- Travel & lodging$9,1454%
- Food & beverage$6,0463%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 158 | $160,661 |
| AstraZeneca | 78 | $43,187 |
| Boehringer Ingelheim | 12 | $4,076 |
| Viiv Healthcare Company | 1 | $600 |
| Genentech USA, Inc. | 27 | $282 |
| Sanofi | 7 | $233 |
| Jazz Pharmaceuticals Inc. | 6 | $222 |
| Grifols USA, LLC | 4 | $84 |
| Novartis | 5 | $75 |
| Philips North America LLC | 4 | $65 |
| Harmony Biosciences LLC | 3 | $57 |
| Circassia Inc. | 4 | $53 |
| Shire North American Group Inc | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Electromed, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$83,769
- BREZTRI$34,584
- TRELEGY ELLIPTA$30,048
- BREZTRI AEROSPHERE$7,133
- ANORO$3,839
- ANORO ELLIPTA$3,600
- XYWAV$150
- XYREM$150
- DUPIXENT$132
- TEZSPIRE$125
- FASENRA$123
How this compares
$209,688 in reported general payments places this provider in the 95th percentile of 58 pulmonary disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 319 | $319,058 |
| OfevNintedanib Esylate | 11 | $178,466 |
| Breo ElliptaFluticasone/Vilanterol | 283 | $153,815 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 238 | $132,120 |
| Spiriva RespimatTiotropium Bromide | 116 | $94,395 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 112 | $83,692 |
| Incruse ElliptaUmeclidinium Bromide | 132 | $58,536 |
| Spiriva HandihalerTiotropium Bromide | 76 | $55,369 |
| NucalaMepolizumab | 12 | $51,403 |
| SymbicortBudesonide/Formoterol Fumarate | 114 | $41,099 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 64 | $40,662 |
| Advair HfaFluticasone Propion/Salmeterol | 68 | $32,249 |
| Arnuity ElliptaFluticasone Furoate | 51 | $14,668 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 74 | $11,918 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 385 | $11,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Nucala | $160,661 | $729,5991,035 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $4,076 | $313,523191 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $43,187 | $129,159237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 58 pulmonary disease providers in Maine.
Other pulmonary disease in Rockport
- Peter BagleyRockport$0
- Jonathan EvansSouth Portland$322K
- Andrew DixonBangor$40K
- Meagan MooreSouth Portland$34K
- Richard RikerSouth Portland$23K
- Misha PeterBangor$9K
- Hal SredenBrunswick$5K
- Donald WoloszynBrunswick$4K
- Robert McArdleLewiston$3K
- Jonathan ZuckermanSouth Portland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.